.gif "IP Gear")
- Joined
- Dec 20, 2007
- Messages
- 578
ok here are the ultra sound results
LV diastole 61.3mm (a little above avg.)
LV systole 43.2mm (a little above avg.)
septum 9.0mm
posterior wall 9.00mm
ejection fraction 56% (>55%) (this i would like to see go back up to around the 60's atleast im wayy too young to have 56% IMO)
aortic valve cusp 25.2mm (11-26mm)
aortic root diam 35.5mm (16-39mm)
Left atrium diam 29.7mm (16-39mm)
RV diastole 23.9mm (<20mm)
this test was taken prior to the cycle. also BP has been in my favor thus far.
also i boosted my ubiquinol intake to 400mgs a day and i truly feel it is helping!! also i found this interesting article that i know a ton of you guys might be interested in
Results of first clinical trial indicate pre-converted form of Coenzyme Q10 positively impacted heart function in critically ill subjects
HOUSTON, Feb. 18 /PRNewswire/ -- Results from the first clinical trial evaluating ubiquinol's effects on late-stage congestive heart failure showed that the newly available pre-converted form of Coenzyme Q10 (CoQ10) dramatically boosted ejection fraction in critically ill patients. Published in the January 2009 issue of Biofactors, a peer-reviewed scientific journal, the year-long study showed that patients' ejection fraction (EF), the capacity at which their heart pumps blood, in some cases more than tripled.
Healthy individuals typically have EF levels of 55 to 70 percent. Damage to the heart muscle, such as that sustained following a heart attack, heart-valve problems, or during myocardial infarction or myocardiomyopathy, impairs the heart's ability to eject blood and therefore reduces EF.
All of the patients that participated in this clinical trial had an EF level below a 35 percent and were classified as New York Heart Association (NYHA) Class IV - a designation that denotes patients' showed symptoms of insufficient heart function while at rest and were unable to carry out any form of physical activity without discomfort. The prognosis for patients with NYHA Class IV heart failure is very poor, with mortality rates as high as 74 percent within 6 months and 94 percent within 12 months.
From June 2006 through May of 2007, the clinical trial followed seven Class IV patients who were under maximal medical therapy and supplementing their treatments with ubiquinone (CoQ10). The study, led by cardiologist Peter Langsjoen, assessed the effect of changing their ubiquinone supplementation to ubiquinol (Kaneka QH(TM)).
When switched to supplemental ubiquinol, there was a dramatic increase in both the patients' EF and plasma CoQ10 l
'/>"/>
SOURCE Kaneka Nutrients L.P.
Copyright©2009 PR Newswire.
All rights reserved
LV diastole 61.3mm (a little above avg.)
LV systole 43.2mm (a little above avg.)
septum 9.0mm
posterior wall 9.00mm
ejection fraction 56% (>55%) (this i would like to see go back up to around the 60's atleast im wayy too young to have 56% IMO)
aortic valve cusp 25.2mm (11-26mm)
aortic root diam 35.5mm (16-39mm)
Left atrium diam 29.7mm (16-39mm)
RV diastole 23.9mm (<20mm)
this test was taken prior to the cycle. also BP has been in my favor thus far.
also i boosted my ubiquinol intake to 400mgs a day and i truly feel it is helping!! also i found this interesting article that i know a ton of you guys might be interested in
Results of first clinical trial indicate pre-converted form of Coenzyme Q10 positively impacted heart function in critically ill subjects
HOUSTON, Feb. 18 /PRNewswire/ -- Results from the first clinical trial evaluating ubiquinol's effects on late-stage congestive heart failure showed that the newly available pre-converted form of Coenzyme Q10 (CoQ10) dramatically boosted ejection fraction in critically ill patients. Published in the January 2009 issue of Biofactors, a peer-reviewed scientific journal, the year-long study showed that patients' ejection fraction (EF), the capacity at which their heart pumps blood, in some cases more than tripled.
Healthy individuals typically have EF levels of 55 to 70 percent. Damage to the heart muscle, such as that sustained following a heart attack, heart-valve problems, or during myocardial infarction or myocardiomyopathy, impairs the heart's ability to eject blood and therefore reduces EF.
All of the patients that participated in this clinical trial had an EF level below a 35 percent and were classified as New York Heart Association (NYHA) Class IV - a designation that denotes patients' showed symptoms of insufficient heart function while at rest and were unable to carry out any form of physical activity without discomfort. The prognosis for patients with NYHA Class IV heart failure is very poor, with mortality rates as high as 74 percent within 6 months and 94 percent within 12 months.
From June 2006 through May of 2007, the clinical trial followed seven Class IV patients who were under maximal medical therapy and supplementing their treatments with ubiquinone (CoQ10). The study, led by cardiologist Peter Langsjoen, assessed the effect of changing their ubiquinone supplementation to ubiquinol (Kaneka QH(TM)).
When switched to supplemental ubiquinol, there was a dramatic increase in both the patients' EF and plasma CoQ10 l
'/>"/>
SOURCE Kaneka Nutrients L.P.
Copyright©2009 PR Newswire.
All rights reserved
